BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Job Trends

  8 Companies Hiring Now in New York

  Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.

  October 30, 2025

   · 

  2 min read

   · 

  Angela Gabriel
• 

  Job Trends

  Almost 1/3 Eyeing Job Options Outside US, BioSpace Finds

  Nearly one-third of biotech and pharma professionals are thinking about leaving the U.S. to find biopharma jobs, according to a BioSpace LinkedIn poll. Career coaches discuss why people are considering relocating and what they should do before heading for the exit.

  October 30, 2025

   · 

  4 min read

   · 

  Angela Gabriel
• 

  Regulatory

  Life-Threatening Liver Toxicity Triggers FDA Freeze on Two Intellia Gene Therapy Studies

  The clinical hold comes days after Intellia voluntarily paused enrollment and dosing in the same two studies.

  October 30, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  Lilly Continues Manufacturing Push With $1.2B Puerto Rico Facility for GLP-1 Pill

  The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of around 1,000 construction-related roles.

  October 30, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  As Biogen Nears Presymptomatic Alzheimer’s Readout for Leqembi, Can Doctors Be Convinced?

  To expand the population for the anti-amyloid Alzheimer’s drugs, Lilly and Biogen are testing presymptomatic patients. Will doctors be open to this paradigm-shifting change?

  October 30, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Earnings

  BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates

  Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives on the company’s investor call faced questions about a sluggish uptake for schizophrenia drug Cobenfy as well as a highly anticipated Alzheimer’s psychosis readout for the product.

  October 30, 2025

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Mergers & acquisitions

  UPDATE: Novo Nordisk Seeks To Steal Metsera From Pfizer With $8.5B Offer

  Pfizer called Novo’s offer “reckless and unprecedented,” in a statement issued Thursday morning.

  October 30, 2025

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  Earnings

  Merck Vaccine Sales Drop as US Declines Strike Another Pharma

  While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

  October 30, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  CAR-T

  Kyverna’s CAR T Therapy Sets ‘New Efficacy Standard’ in Myasthenia Gravis, De-Risking Phase III Trials

  With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to analysts at William Blair.

  October 30, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Zepbound Topples Sales King Keytruda as Lilly Reports 54% YoY Revenue Rise for Q3

  Mounjaro and Zepbound contributed more than $10 billion to the $11.98 billion in sales Lilly recorded for key products in the third quarter, despite price decreases for the GLP-1 medicines.

  October 30, 2025

   · 

  1 min read

   · 

  Annalee Armstrong